Abraxane (Celgene) success in Phase III study of Pancreatic Cancer
In a Phase III study,(the MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial), Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound),from Celgene, in combination with gemcitabine in treatment-na�ve patients with advanced Pancreatic Cancer met its primary endpoint of overall survival. In the study, Abraxane in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone.
A late-breaker placeholder abstract for this study has been submitted to the American Society of Clinical Oncology�s (ASCO) 2013 Gastrointestinal Cancers Symposium being held in San Francisco on January 24-26, 2013.
Based on the results of the MPACT study, the company plans to submit dossiers for registration in the US, Europe and other markets.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins